A randomised, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalised Anxiety Disorder (GAD).
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2015
At a glance
- Drugs BNC 210 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms 2BMC1
- 20 Apr 2015 According to Bionomics media release, the results are expected in third quarter of 2016.
- 20 Apr 2015 According to Bionomics media release, status changed from planning to recruiting.
- 13 Nov 2014 New trial record